A Phase 3 Study of Patidegib Gel for Basal Cell Carcinoma Prevention

Active, Not Recruiting Phase 3 NCT06050122

Study Description

Evaluating the Effectiveness and Safety of a Topical Gel (Patidegib Gel 2%) in Preventing New Basal Cell Skin Cancers on the Face in Adults with Gorlin Syndrome

Study Details

Registry ID:: NCT06050122
Conditions:: Gorlin Syndrome
Phase:: Phase 3
Target Enrollment:: 140 participants
Start Date:: March 17, 2024
Healthy Volunteers:: No

Study Locations (42 sites)

Hospital Universitartio 12 De Octubre
MadridSpain, Spain
Hospital de la Santa Creu i Sant Pau
BarcelonaSpain, Spain
Hospital Clinic Barcelona
BarcelonaSpain, Spain
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
RomeItaly, Italy
Centre Hospitalier Lyon Sud
Pierre-BéniteFrance, France
AOU Maggiore della Carita
NovaraItaly, Italy
ASST Spedali Civili di Brescia
BresciaItaly, Italy
Centre Hospitalier Universitaire De Nantes
NantesFrance, France
Hopital Avicenne
BobignyFrance, France
Ludwig-Maximilians-Universitaet Muenchen (LMU) - Klinik und Poliklinik fuer Dermatologie und Allergologie
Munich, BavariaGermany, Germany
Maastricht University Medical Center
MaastrichtNetherlands, Netherlands
Barts Health NHS Trust - The Royal London Hospital
LondonUnited Kingdom, United Kingdom
DRK Gemeinnützige Krankenhaus GmbH Sachsen
ChemnitzGermany, Germany
The University of Birmingham
BirminghamUnited Kingdom, United Kingdom
Ludwig-Maximilians-Universitaet Muenchen (LMU) - Klinik und Poliklinik fuer Dermatologie und Allergologie
Muenchen, BayernGermany, Germany
Northern Care Alliance NHS Foundation Trust
SalfordUnited Kingdom, United Kingdom
Charité Universitätsmedizin Berlin - Campus Charité Mitte
BerlinGermany, Germany
Yale University
New Haven, ConnecticutUnited States, United States
Memorial Sloan Kettering Cancer Center
New York, New YorkUnited States, United States
Schweiger Dermatology P.C.
Verona, New JerseyUnited States, United States
The Johns Hopkins Hospital
Baltimore, MarylandUnited States, United States
Penn State Hershey Medical Center
Hershey, PennsylvaniaUnited States, United States
Duke University Health System
Durham, North CarolinaUnited States, United States
University of South Florida Health
Tampa, FloridaUnited States, United States
Dermatology Associates of Tallahassee
Tallahassee, FloridaUnited States, United States
Apex Clinical Research Center
Canton, OhioUnited States, United States
Apex Clinical Research Center
Mayfield Heights, OhioUnited States, United States
Cleveland Clinic - Main Campus
Cleveland, OhioUnited States, United States
University of Michigan Health - Michigan Medicine - University Hospital
Ann Arbor, MichiganUnited States, United States
The University of Chicago Medicine
Chicago, IllinoisUnited States, United States
The University of Texas MD Anderson Cancer Center
Houston, TexasUnited States, United States
Northwest Arkansas Clinical Trials Center
Rogers, ArkansasUnited States, United States
North Texas Center for Clinical Research
Frisco, TexasUnited States, United States
MediSearch Clinical Trials
St Joseph, MissouriUnited States, United States
MediSearch Clinical Trials
Saint Joseph, MissouriUnited States, United States
Minnesota Clinical Study Center
New Brighton, MinnesotaUnited States, United States
SSM Health Dermatology
Oklahoma City, OklahomaUnited States, United States
The Dermatology Center of Newport
Newport Beach, CaliforniaUnited States, United States
University of California Los Angeles (UCLA) - Center for Inflammatory Bowel Diseases - Westwood Location
Los Angeles, CaliforniaUnited States, United States
Center for Dermatology Clinical Research
Fremont, CaliforniaUnited States, United States
Stanford University - Lucille Packard's Children's Hospital
Redwood City, CaliforniaUnited States, United States
Oregon Health and Science University
Portland, OregonUnited States, United States

Interested in Participating?

Check your eligibility and learn more about this study on TrialScreen.org.

View full study details and check eligibility →